Ira Pastan American scientist
Pastan, Ira H.
Pastan, Ira
Pastan, Ira H., 1931-
Pastan, Ira H., 19..-....
פסטן, איירה
VIAF ID: 54278349 (Personal)
Permalink: http://viaf.org/viaf/54278349
Preferred Forms
- 100 0 _ ‡a Ira Pastan ‡c American scientist
- 200 _ | ‡a Pastan ‡b Ira H.
- 100 1 _ ‡a Pastan, Ira
-
-
- 100 1 _ ‡a Pastan, Ira H. (sparse)
- 100 1 _ ‡a Pastan, Ira H.
-
-
-
-
- 100 1 _ ‡a Pastan, Ira H., ‡d 19..-....
-
-
4xx's: Alternate Name Forms (9)
Works
Title | Sources |
---|---|
Cell culture | |
Endocytosis, c1985: | |
Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE. | |
Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia | |
Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). | |
Immunoconjugates in the management of hairy cell leukemia | |
Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs | |
Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine | |
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. | |
The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan | |
Improving the in vivo efficacy of an anti-Tac (CD25) immunotoxin by Pseudomonas exotoxin A domain II engineering. | |
In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma | |
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin | |
Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. | |
Isolation of anti-CD22 Fv with high affinity by Fv display on human cells | |
Lipoprotein modulation of proteinuric renal injury | |
Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor | |
Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin. | |
Mammalian cell display for antibody engineering | |
Mechanisms of Resistance to Immunotoxins Containing Pseudomonas Exotoxin A in Cancer Therapy | |
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors | |
Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats | |
Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8. | |
MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer | |
Multiple proteases are involved in mesothelin shedding by cancer cells | |
Mutants of immunotoxin anti-Tac(dsFv)-PE38 with variable number of lysine residues as candidates for site-specific chemical modification. 1. Properties of mutant molecules | |
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy | |
New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma | |
New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. | |
NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate | |
NGEP, a prostate-specific plasma membrane protein that promotes the association of LNCaP cells. | |
Non-AUG translational initiation of a short CAPC transcript generating protein isoform | |
A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity | |
Palmitoylation of POTE family proteins for plasma membrane targeting | |
PATE, a gene expressed in prostate cancer, normal prostate, and testis, identified by a functional genomic approach | |
PATE gene clusters code for multiple, secreted TFP/Ly-6/uPAR proteins that are expressed in reproductive and neuron-rich tissues and possess neuromodulatory activity | |
The PATE gene is expressed in the accessory tissues of the human male genital tract and encodes a secreted sperm-associated protein | |
Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts | |
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia | |
Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A. | |
Possible role of complement factor H in podocytes in clearing glomerular subendothelial immune complex deposits | |
POTE protein, a cancer-testis antigen, is highly expressed in spermatids in human testis and is associated with apoptotic cells | |
A primate-specific POTE-actin fusion protein plays a role in apoptosis | |
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig | |
Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A. | |
Pseudomonas exotoxin antisense RNA selectively kills hepatitis B virus infected cells | |
Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors | |
Recognition of Mesothelin by the Therapeutic Antibody MORAb-009: STRUCTURAL AND MECHANISTIC INSIGHTS | |
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity | |
A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity. | |
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes | |
Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins | |
Removing T-cell epitopes with computational protein design. | |
Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera | |
Selective POTE paralogs on chromosome 2 are expressed in human embryonic stem cells. | |
Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers | |
SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors | |
Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study | |
Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy. | |
The T cell receptor gamma chain alternate reading frame protein (TARP), a prostate-specific protein localized in mitochondria | |
Targeted cytotoxic therapy kills persisting HIV infected cells during ART | |
Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin | |
Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies | |
TEPP, a new gene specifically expressed in testis, prostate, and placenta and well conserved in chordates | |
Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. | |
Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level | |
Toxin-based targeted therapy for malignant brain tumors | |
TP-3 immunotoxins improve antitumor activity in mice with osteosarcoma. | |
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates |